Am J Perinatol 2019; 36(S 02): S18-S21
DOI: 10.1055/s-0039-1691772
Review Article
Thieme Medical Publishers 333 Seventh Avenue, New York, NY 10001, USA.

Neonatal Therapeutics: Considerations for Dosing

Kanecia O. Zimmerman
1  Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
2  Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina
,
Daniel K. Benjamin
1  Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
2  Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina
,
Mara L. Becker
1  Duke Clinical Research Institute, Duke University School of Medicine, Durham, North Carolina
2  Department of Pediatrics, Duke University School of Medicine, Durham, North Carolina
› Author Affiliations
Further Information

Publication History

Publication Date:
25 June 2019 (online)

Abstract

Neonates are a uniquely vulnerable population, compromised by immature physiology and critical illness if born premature. Furthermore, neonates have frequent exposures to drugs that lack adequate data on safety, efficacy, and appropriate dosing in this population. Key physiologic differences between neonates and older children and adults affect drug absorption, distribution, metabolism, and elimination. Adequate understanding and consideration of these differences is essential to ensure optimal dosing of therapeutic agents in this vulnerable population. Moreover, direct study of neonates through appropriately designed pharmacokinetic and pharmacodynamic studies can ensure the development of safe and effective therapeutics in our youngest populations of patients.